News|Articles|November 2, 2026

AAPS PharmSci 360 2026: 5 Takeaways on AI, Oral Peptides, and Antibody Costs

AAPS PharmSci 360 2026 in New Orleans centered on auditable AI, modeling-guided formulation, oral peptide delivery, high-concentration antibody suspensions, and the push toward $10-per-gram monoclonal antibodies.

AAPS PharmSci 360 2026 brought pharmaceutical scientists to the Ernest N. Morial Convention Center in New Orleans from October 25 to 28, and the program kept returning to one question: how to make drug development smarter, not just faster. Julie Gerberding, MD, MPH, president and chief executive officer of the Foundation for the National Institutes of Health (FNIH), opened the meeting on October 25 with a plenary titled "Adaptive Intelligence: Accelerating Biomedical Innovation," which covered artificial intelligence (AI), adaptive clinical trials, and novel alternative methods for drug development.¹ Below are five takeaways from BioPharm International®'s coverage of the meeting, which are also featured in our video recap.

Related to this article

October 30th, 2026

18-Month Room-Temperature Data Support Hyaluronidase-Free Antibody Suspensions, Says Nanoform’s Chris Worrall

In an interview for BioPharm International’s AAPS PharmSci 360 2026 coverage, Nanoform’s Chris Worrall shares 18-month stability data for a 440 mg/mL trastuzumab suspension and explains how ultra-high-concentration formulations could shorten administration and support at-home injection.

October 29th, 2026

Antibody Manufacturing Costs Have Fallen From $35 to About $12 per Gram, Says IIT Delhi’s Anurag Rathore

In the final part of a three-part interview, Anurag Rathore, PhD, professor of chemical engineering at IIT Delhi, explains how his team has cut monoclonal antibody costs toward $10 per gram and why process intensification will spread one unit operation at a time.

October 29th, 2026

Non-Aqueous Suspensions Could Push Antibody Concentrations Above 400 mg/mL, Says Nanoform’s Chris Worrall

As part of BioPharm International’s AAPS PharmSci 360 2026 coverage, Nanoform’s Chris Worrall explains why stability and viscosity have kept antibody formulations below 200 mg/mL, and how a low-temperature particle engineering process and non-aqueous suspensions could support ultra-high concentrations.

October 28th, 2026

$10-per-Gram Antibodies Could Compete With Vaccines Against Infectious Disease, Says IIT Delhi’s Anurag Rathore

Anurag Rathore, PhD, professor of chemical engineering at IIT Delhi, explains how his team cuts monoclonal antibody costs without cutting purification steps, and why the $10-per-gram target could make antibodies viable for infectious disease and global access.

White powder in a round glass Petri dish on a blue background, with a wooden spatula resting in the dish and holding a small mound of the powder. | Image Credit: © AB-7272 - stock.adobe.com

October 27th, 2026

Thermo Fisher Pairs In Silico Modeling With an Expanded ASD Toolbox at AAPS PharmSci 360

At AAPS PharmSci 360, Thermo Fisher Scientific scientists described how predictive modeling guides technology selection for poorly soluble drugs, and outlined plans to bring solvent-free KinetiSol technology to commercial scale in 2027.

3D illustration of orange-yellow antibodies binding to Y-shaped receptors on a blue cell surface against a dark background, with another antibody floating in the distance. | Image Credit: © Tatiana Shepeleva - stock.adobe.com

November 2nd, 2026

Fresenius and WuXi Biologics Sign Exclusive Agreement Covering Up to 37 Biosimilar Candidates

The deal gives Fresenius options on biosimilars spanning monoclonal and bispecific antibodies, ADCs, and fusion proteins, starting with polatuzumab vedotin and teprotumumab, and could expand its portfolio from 29 to 66 molecules.

Grid of black-and-white brain CT scans with a blue tint, showing cross-sections of the head from the top, front, and side. | Image Credit: © photoprofi30 - stock.adobe.com

November 2nd, 2026

FDA Accepts uniQure’s Huntington’s Disease Gene Therapy BLA for Priority Review

FDA set a May 1, 2027 target date for AMT-130, a one-time gene therapy that silences the huntingtin gene, and plans an advisory committee meeting.

October 30th, 2026

AAPS 2026 PharmSci 360 Video Recap: AI Transparency, Oral Peptides, and New Models

This year’s AAPS PharmSci 360 highlighted AI transparency, computer modeling in formulation, oral peptide delivery, and new business models.